Phase II study identifies potential biomarkers in HPV-positive anal cancer
Cytotoxic chemotherapy is the standard of care for patients with unresectable and metastatic squamous cell carcinoma of the anal canal – a rare type of anal cancer often linked to human papillomavirus (HPV) infection. However, this treatment has limited efficacy, and patients have a poor prognosis. To address this, researchers led by Van Morris, M.D., conducted a Phase II trial to evaluate the combination of the anti-PD-L1...
Bioinformatics chatbot can analyze large-scale cancer proteomics data
Comprehensive cancer omics initiatives like The Cancer Genome Atlas (TCGA) provide a wealth of DNA and RNA data, but little is known about...
Combination therapy yields strong long-term overall response rate in newly diagnosed acute myeloid leukemia patients
Intensive chemotherapy remains the standard treatment option for medically fit patients with newly diagnosed acute myeloid leukemia (AML)....
Study offers insights into evolutionary process driving pancreatic cancer aggressiveness
Pancreatic cancer is hard to treat because of its heterogeneity, a characteristic frequently sustained by the ability of cells to change states. One example is epithelial-to-mesenchymal transition (EMT), in which epithelial cells become more mobile. While EMT plays a critical role in many cellular processes, cancer cells have leveraged EMT to promote treatment resistance and metastasis. To better understand its functional role in...
Researchers identify epigenetic biomarker for breast cancer metastatic relapse
Cancer cells that initiate metastasis at secondary sites often enter a dormant state, allowing them to evade treatment and later reawaken...
Surgery enhances immunotherapy in advanced kidney cancer
Patients with advanced solid tumors are usually ineligible for surgery. However, surgically removing the primary tumor in preclinical models...